Find clinical trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Find sexual health research studies
Clear filter
604 clinical trials found
Clinical trials

ACEMID

Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Cohort Study (ACTRN12619001706167)

Currently recruiting

ACT17967

ACT17967 - A phase 2, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa (NCT06118099)

Currently recruiting

ACTIVATE AVF

A study of the safety and feasibility of the Vessel Restoration System for AVF to promote the physiologic and functional maturation of upperextremity autologous End-to-Side Arteriovenous Fistulas (AVF) in Patients with Chronic Kidney Disease: ACTIVATE AVF (NCT05462223)

Recently completed/closed

ACTIVATE II

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA): ACTIVATE II (NCT05454995)

Recently completed/closed

ACTM-838

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors (NCT06336148)

Currently recruiting

ADAPT-TDM

A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)

Currently recruiting

ADOPT-LUNG ETOP 25-23

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC (ACTRN12624001373561)

Currently recruiting

ADVANCE-extension

A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)

Currently recruiting

ADVANCE-outcomes

A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)

Currently recruiting

AER-01

A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose [AER-01] Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06731959)

Currently recruiting

AFFINE

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C<=1%) (NCT04370054)

No longer recruiting

AFMR_TTE

Outcomes of Surgery for Atrial Functional Mitral Regurgitation (ACTRN12624000705583)

Currently recruiting

AHSCT in MS

A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)

Currently recruiting

AIE001

A randomised, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of rozanolixizumab in adult study participants with leucine-rich glioma inactivated 1 autoimmune encephalitis (NCT04875975)

Recently completed/closed

AK-US-001-0105 - NASH

A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (NCT06215716)

Currently recruiting

AK-US-001-0106

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/Metabolic Dysfunction-Associated Steatohepatitis [MASH] (NCT06528314)

Currently recruiting

AK-US-001-0107 - NASH

A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed nonalcohol steatohepatitis (NASH)/ Nonalcoholic fatty liver disease (NAFLD). (NCT06161571)

Currently recruiting

Alterity ATH

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy (NCT05109091)

Currently recruiting

AMaRC 21-04

Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)

Currently recruiting

AMEND-CRT

Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)

Currently recruiting
1 2 3 4